- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Inhibikase Therapeutics files $300M mixed securities shelf | 1 | Seeking Alpha | ||
| 14.05. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | 1 | FierceBiotech | ||
| 14.04. | Inhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-market | - | RTTNews | ||
| 14.04. | Inhibikase Therapeutics appoints new CFO | 2 | Investing.com | ||
| 14.04. | Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise | 1 | Seeking Alpha | ||
| 14.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock | 3 | Investing.com | ||
| 27.03. | Inhibikase Therapeutics GAAP EPS of -$1.16 | 1 | Seeking Alpha | ||
| 27.03. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 391 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen | |
| 24.02. | Inhibikase enhances leadership with new appointments | 1 | Investing.com | ||
| 18.02. | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 177 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen | |
| 18.02. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.01. | Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug | 1 | FierceBiotech | ||
| 29.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 159,20 | 0,00 % | Aktienmarkt: Kurs der Aktie von AbbVie im Plus (159,9573 €) | Die Aktie von AbbVie notiert heute ein wenig fester. Das Papier kostete zuletzt 185,88 US-Dollar. Der Anteilsschein von AbbVie verzeichnet zur Stunde einen Preisanstieg von 1,15 Prozent. Er hat sich... ► Artikel lesen | |
| TEVA | 14,300 | -2,05 % | Teva Pharmaceutical Industries Ltd: Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY (fremanezumab) für die Prävention chronischer und episodischer Migräne | Die abschließende Analyse der realen PEARL-Studie für die Migräneprävention wurde auf dem 11. Kongress der European Academy of Neurology (EAN 2025) in Helsinki präsentiert1,2Fremanezumab demonstrierte... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 8,700 | -3,87 % | EyePoint Pharmaceuticals, Inc. - 8-K, Current Report | ||
| BAUSCH HEALTH | 5,494 | +0,31 % | Bausch Health Companies Inc: Bausch Health Announces 2025 Annual Meeting of Shareholder Results | LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,150 | +1,77 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 02.04.2025 | The following instruments on XETRA do have their first trading 02.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.04.2025
Aktien
1 ROMEDLACNOR6 MedLife S.A.
2 CA29872T2092... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 17,600 | -16,19 % | Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering | ||
| ASTRIA THERAPEUTICS | 4,720 | -2,48 % | Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress | -- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 92,24 | +0,39 % | Jazz Pharmaceuticals plc: Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer | Target Action (PDUFA) Date set for October 7, 2025
Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,664 | +5,05 % | SELLAS Life Sciences wird in Russell 3000 und Russell 2000 Indizes aufgenommen | ||
| MADRIGAL PHARMACEUTICALS | 249,00 | +4,40 % | AKTIONÄR-Hot-Stock Madrigal mit Top-News: Gamechanger-Therapie vor EU-Zulassung | Zwischen dem 16. und 19. Juni hat der Ausschuss für Humanarzneimittel (CHMP) von der europäischen Arzneimittelbehörde (EMA) erneut getagt und Zulassungsanträge von Biotech- respektive Pharma-Unternehmen... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,710 | -0,56 % | XORTX Therapeutics Inc.: XORTX Announces USD $925,000 Private Placement | ||
| BRIDGEBIO PHARMA | 38,000 | -0,21 % | BridgeBio Pharma, Inc.: BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET | ||
| VERONA PHARMA PLC ADR | 80,20 | -1,96 % | Kursziel für Verona Pharma auf 160 US-Dollar von 76 US-Dollar bei Piper Sandler angehoben | ||
| OPUS GENETICS | 0,847 | +2,54 % | Opus Genetics, Inc.: Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia | Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 16,100 | +0,62 % | Rigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business Update | First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of... ► Artikel lesen |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,60 % bei einem Aktienkurs von 1,675 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.